BridgeMD
New treatment option for Burns
Official title Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults
ClinicalTrials.gov ID: NCT06469970
What this study is testing
What is Glucose 30% Intravenous Solution?
Glucose 30% Intravenous Solution is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for burns.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a prospective, observational, monocentric, phase II (exploratory) cohort study aiming to describe the evolutionary profile of the initial volume of glucose distribution (IDVG) during the first four days of management of severely burned patient.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients over 18 years of age
- Patients hospitalized with burns of at least 30% of body surface area
- By a thermal mechanism
- At the CHR Metz-Thionville burn center
- managed within the 8 hours post-burn
You likely can't join if
- Diabetic patients on insulin
- Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection
- Patients with pre-hospital cardiac arrest
- extra corporeal circulation patient: Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal...
- patient without a central venous line or arterial catheter
- Patient moribund or immediately subject to therapeutic limitation
See the full eligibility criteria
- Patients over 18 years of age
- Patients hospitalized with burns of at least 30% of body surface area
- By a thermal mechanism
- At the CHR Metz-Thionville burn center
- managed within the 8 hours post-burn
- Patient affiliated to a social security scheme
- Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither...
- Diabetic patients on insulin
- Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection
- Patients with pre-hospital cardiac arrest
- extra corporeal circulation patient: Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy)
- patient without a central venous line or arterial catheter
- Patient moribund or immediately subject to therapeutic limitation
- Impossibility of trans-pulmonary thermodilution monitoring (vascular access difficulties)
- Pregnant, parturient or breast-feeding women
- Patient under guardianship, curatorship or safeguard of justice
- Cognitive impairment or language barrier
The study team makes the final eligibility decision.
Where it's taking place
- Metz, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Metz, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.